Camp4 Therapeutics Corp
For the period ended Dec 31, 2025. Filed Mar 5, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Mar 5, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 9B. Other Information
On December 22, 2025, Josh Mandel-Brehm, ourchief executive officer and a member of our board of directors, adopted a trading plan intended to satisfy the conditions specified in Rule 10b5-1(c) under the Exchange Act for an affirmative defense against liability for trading in securities on the basis of material nonpublic information. Pursuant to this plan, Mr. Mandel-Brehm may sell up to 163,414 shares of our common stock received upon the settlement of awards granted to Mr. Mandel-Brehm as equity incentive compensation beginning on March 23, 2026, subject to the terms of the plan. The plan will terminate on or prior to March 23, 2027.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.